Table 4.
Characteristics of pachychoroid neovasculopathy in subretinal hemorrhage group and non- subretinal-hemorrhage group.
| SRH group (n = 20) |
Non-SRH group (n = 79) |
P value | |
|---|---|---|---|
| Gender (men/women) | 17/3 | 62/17 | 0.517** |
| Age (years), mean ± SD | 66.2 ± 9.5 | 70.1 ± 7.6 | 0.053* |
| Axial length (mm) | 23.37 ± 0.91 | 23.36 ± 0.91 | 0.959* |
| Hypertension (%) | 8 (40.0) | 45 (57.0) | 0.174** |
| Smoking (%) | 15 (75.0) | 56 (70.9) | 0.775** |
| Follow-up period (months), mean ± SD | 35.0 ± 18.9 | 38.0 ± 17.4 | 0.525* |
| Initial conditions | |||
| BCVA (logMAR), mean ± SD | 0.27 ± 0.55 | 0.18 ± 0.24 | 0.455* |
| Lesion area (mm2), mean ± SD | 2.48 ± 3.21 | 3.50 ± 3.30 | 0.363* |
| GLD (µm), mean ± SD | 4698 ± 2302 | 2909 ± 1519 | 0.005* |
| CRT (µm), mean ± SD | 417.1 ± 365.8 | 296.7 ± 130.1 | 0.163* |
| SFCT (µm), mean ± SD | 310.3 ± 53.1 | 306.9 ± 70.9 | 0.845* |
| Polypoidal lesion (%) | 17 (85.0) | 38 (48.1) | 0.004** |
| CVH (%) | 11 (55.0) | 45 (57.0) | 0.211** |
| Final conditions | |||
| BCVA (logMAR), mean ± SD | 0.55 ± 0.60 | 0.12 ± 0.26 | 0.005* |
| CRT (µm), mean ± SD | 153.2 ± 99.7 | 178.7 ± 89.3 | 0.266* |
SRH subretinal hemorrhage; SD standard deviation; BCVA best-corrected visual acuity; GLD greatest linear dimension; CRT central retinal thickness; SFCT subfoveal choroidal thickness; CVH choroidal vascular hyperpermeability.
*Unpaired t-test, **Chi-square test.